AbL Diagnostics SA
ABL Diagnostics Société anonyme provides proprietary molecular biology assays and end-to-end solutions to be used for molecular detection by polymerase chain reaction (PCR) and through DNA sequencing in France and internationally. The company offers genotyping through NGS and sanger sequencing for human immunodeficiency virus, SARS CoV-2, hepatitis-C virus, mycobacterium tuberculosis, and 16S/18S… Read more
AbL Diagnostics SA (ABLD) - Net Assets
Latest net assets as of June 2025: €6.93 Million EUR
Based on the latest financial reports, AbL Diagnostics SA (ABLD) has net assets worth €6.93 Million EUR as of June 2025.
Net assets (also known as shareholders' equity or book value) represent the difference between a company's total assets (€11.10 Million) and total liabilities (€4.17 Million). This figure indicates the residual interest in the assets after deducting liabilities, essentially showing what would remain for shareholders if all assets were liquidated and all debts paid off.
Key Net Assets Metrics
| Metric | Value |
|---|---|
| Current Net Assets | €6.93 Million |
| % of Total Assets | 62.4% |
| Annual Growth Rate | 2.59% |
| 5-Year Change | 217.07% |
| 10-Year Change | 13.17% |
| Growth Volatility | 41.02 |
AbL Diagnostics SA - Net Assets Trend (2007–2024)
This chart illustrates how AbL Diagnostics SA's net assets have evolved over time, based on quarterly financial data. Explore and compare other companies by net assets.
Annual Net Assets for AbL Diagnostics SA (2007–2024)
The table below shows the annual net assets of AbL Diagnostics SA from 2007 to 2024.
| Year | Net Assets | Change |
|---|---|---|
| 2024-12-31 | €7.49 Million | +10.62% |
| 2023-12-31 | €6.77 Million | +0.20% |
| 2022-12-31 | €6.75 Million | +157.88% |
| 2021-12-31 | €2.62 Million | +10.92% |
| 2020-12-31 | €2.36 Million | -66.70% |
| 2019-12-31 | €7.09 Million | -0.88% |
| 2018-12-31 | €7.15 Million | -2.98% |
| 2017-12-31 | €7.37 Million | +9.15% |
| 2016-12-31 | €6.76 Million | +2.11% |
| 2015-12-31 | €6.62 Million | +2.98% |
| 2014-12-31 | €6.42 Million | +12.95% |
| 2013-12-31 | €5.69 Million | +9.20% |
| 2012-12-31 | €5.21 Million | +2.18% |
| 2011-12-31 | €5.10 Million | +0.82% |
| 2010-12-31 | €5.06 Million | +0.68% |
| 2009-12-31 | €5.02 Million | +1.07% |
| 2008-12-31 | €4.97 Million | +2.57% |
| 2007-12-31 | €4.84 Million | -- |
Equity Component Analysis
This analysis shows how different components contribute to AbL Diagnostics SA's total equity over time. Equity components include common stock, retained earnings, additional paid-in capital, and other elements.
Equity Composition Insights
- Retained earnings have grown by 241811400.0% over the analyzed period, indicating profitable operations and earnings retention.
Current Equity Component Breakdown (December 2024)
| Component | Amount | Percentage |
|---|---|---|
| Retained Earnings | €2.25 Million | 29.99% |
| Common Stock | €1.61 Million | 21.52% |
| Other Components | €3.63 Million | 48.49% |
| Total Equity | €7.49 Million | 100.00% |
AbL Diagnostics SA Competitors by Market Cap
The table below lists competitors of AbL Diagnostics SA ranked by their market capitalization.
| Company | Market Cap |
|---|---|
|
NedSense Enterprises NV
AS:NEDSE
|
$401.94K |
|
AS Trigon Property Development
STU:UG4
|
$402.03K |
|
Anfield Resources Inc
OTCQB:ANLDF
|
$402.03K |
|
ATHOS IMMO (IJM.SG)
STU:IJM
|
$402.05K |
|
METCH INTL LTD. SD -25
F:VZ3P
|
$401.54K |
|
MAKEMYTRIP (MY1.SG)
STU:MY1
|
$401.40K |
|
Arian Resources Corp.
V:ARC
|
$401.30K |
|
ARES-P-B
PINK:ARES-P-B
|
$401.21K |
Equity Growth Attribution
This analysis shows how different factors contributed to changes in AbL Diagnostics SA's equity between the two most recent reporting periods.
Equity Growth Insights
- From 2023 to 2024, total equity changed from 6,767,753 to 7,486,651, a change of 718,898 (10.6%).
- Net income of 285,170 contributed positively to equity growth.
- Other factors increased equity by 433,728.
Equity Change Factors (2023 to 2024)
| Factor | Impact | Contribution |
|---|---|---|
| Net Income | €285.17K | +3.81% |
| Other Changes | €433.73K | +5.79% |
| Total Change | €- | 10.62% |
Book Value vs Market Value Analysis
This analysis compares AbL Diagnostics SA's book value (net assets) with its market value over time. The relationship between these values can provide insights into investor sentiment and company valuation.
Valuation Insights
- Current price-to-book ratio: 6.93x
- The company is trading at a significant premium to its book value, suggesting the market values its earnings potential, brand, or other intangibles highly.
- The price-to-book ratio has increased from 0.17x to 6.93x over the analyzed period, suggesting growing market confidence.
Historical Price-to-Book Ratios
| Date | Book Value per Share | Market Price | P/B Ratio |
|---|---|---|---|
| 2007-12-31 | €19.31 | €3.22 | x |
| 2008-12-31 | €19.81 | €3.22 | x |
| 2009-12-31 | €20.02 | €3.22 | x |
| 2010-12-31 | €20.16 | €3.22 | x |
| 2011-12-31 | €20.32 | €3.22 | x |
| 2012-12-31 | €20.77 | €3.22 | x |
| 2013-12-31 | €23.72 | €3.22 | x |
| 2014-12-31 | €29.26 | €3.22 | x |
| 2015-12-31 | €23.55 | €3.22 | x |
| 2016-12-31 | €27.08 | €3.22 | x |
| 2017-12-31 | €29.40 | €3.22 | x |
| 2018-12-31 | €28.52 | €3.22 | x |
| 2019-12-31 | €28.27 | €3.22 | x |
| 2020-12-31 | €9.41 | €3.22 | x |
| 2021-12-31 | €10.45 | €3.22 | x |
| 2022-12-31 | €0.42 | €3.22 | x |
| 2023-12-31 | €0.42 | €3.22 | x |
| 2024-12-31 | €0.46 | €3.22 | x |
Capital Efficiency Dashboard
This dashboard shows how efficiently AbL Diagnostics SA utilizes its equity to generate returns, including Return on Equity (ROE) and its components based on the DuPont analysis framework.
Capital Efficiency Insights
- Current Return on Equity (ROE): 3.81%
- The company may be facing challenges in efficiently utilizing shareholder equity.
- DuPont Analysis Breakdown:
- • Net Profit Margin: 5.35%
- • Asset Turnover: 0.45x
- • Equity Multiplier: 1.58x
- Recent ROE (3.81%) is above the historical average (1.18%), indicating improving capital efficiency.
Historical Capital Efficiency Metrics
| Year | Return on Equity | Net Profit Margin | Asset Turnover | Equity Multiplier | Economic Value Added |
|---|---|---|---|---|---|
| 2007 | 2.21% | 731.01% | 0.00x | 1.01x | €-377.58K |
| 2008 | 2.51% | 792.05% | 0.00x | 1.01x | €-372.12K |
| 2009 | 1.42% | 49.75% | 0.03x | 1.01x | €-430.72K |
| 2010 | 0.68% | 24.61% | 0.03x | 1.02x | €-471.33K |
| 2011 | 0.82% | 28.77% | 0.03x | 1.02x | €-468.11K |
| 2012 | 2.13% | 878.26% | 0.00x | 1.02x | €-409.62K |
| 2013 | 8.43% | 4442.40% | 0.00x | 1.04x | €-89.18K |
| 2014 | 10.25% | 1885.37% | 0.01x | 1.02x | €16.22K |
| 2015 | -4.25% | -87.24% | 0.04x | 1.12x | €-942.53K |
| 2016 | -7.39% | -90.71% | 0.08x | 1.02x | €-1.17 Million |
| 2017 | -0.34% | -3.83% | 0.09x | 1.02x | €-762.41K |
| 2018 | -6.36% | -132.52% | 0.04x | 1.08x | €-1.17 Million |
| 2019 | -0.80% | 0.00% | 0.00x | 1.02x | €-765.66K |
| 2020 | -3.70% | 0.00% | 0.00x | 1.01x | €-323.55K |
| 2021 | -5.37% | 0.00% | 0.00x | 1.04x | €-402.61K |
| 2022 | 16.37% | 12.64% | 0.57x | 2.28x | €430.25K |
| 2023 | 0.80% | 0.97% | 0.38x | 2.20x | €-622.42K |
| 2024 | 3.81% | 5.35% | 0.45x | 1.58x | €-463.50K |
Industry Comparison
This section compares AbL Diagnostics SA's net assets metrics with peer companies in the Health Information Services industry.
Industry Context
- Industry: Health Information Services
- Average net assets among peers: $52,062,370
- Average return on equity (ROE) among peers: -67.45%
Peer Company Comparison
| Company | Net Assets | Return on Equity | Debt-to-Equity | Market Cap |
|---|---|---|---|---|
| AbL Diagnostics SA (ABLD) | €6.93 Million | 2.21% | 0.60x | $401.58K |
| AMA Corp PLC (ALAMA) | $26.90 Million | -36.57% | 0.42x | $2.09 Million |
| Intrasense (ALINS) | $1.65 Million | -341.90% | 3.65x | $4.69 Million |
| SMAIO SA (ALSMA) | $1.79 Million | -94.52% | 1.15x | $7.78 Million |
| Cegedim S.A. (CGM) | $242.05 Million | 13.91% | 4.36x | $55.75 Million |
| Equasens S. A. (EQS) | $38.61 Million | 23.58% | 1.03x | $174.86 Million |
| Media Lab SpA (MLLAB) | $1.37 Million | 30.81% | 0.42x | $31.45K |